*ST美谷(000615) - 2021 Q4 - 年度财报

Business Transformation - The company reported a significant change in its main business, shifting from real estate and chemical fiber new materials to focusing on chemical fiber new materials and medical beauty services[18]. - The company has undergone a major asset sale related to its real estate business, with the relevant companies completing industrial and commercial change registration[4]. - The company has completed significant asset restructuring, divesting 100% of its real estate business and focusing on medical beauty and chemical fiber new materials as its main business[34]. - The company is in the process of changing its industry classification, pending approval from the China Securities Regulatory Commission[5]. - The company has divested its real estate business, focusing on the beauty and health industry, which is expected to enhance its core competitiveness[48]. Financial Performance - The company's operating revenue for 2021 was approximately ¥1.54 billion, a decrease of 22.58% compared to ¥1.99 billion in 2020[20]. - The net profit attributable to shareholders was a loss of approximately ¥253.37 million, representing an 88.03% increase in losses compared to a loss of ¥134.75 million in 2020[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of approximately ¥671.50 million, a 234.01% increase in losses compared to a loss of ¥201.04 million in 2020[20]. - The total assets at the end of 2021 were approximately ¥4.32 billion, a decrease of 54.29% from ¥9.45 billion at the end of 2020[20]. - The net assets attributable to shareholders at the end of 2021 were approximately ¥1.47 billion, a decrease of 14.48% from ¥1.71 billion at the end of 2020[20]. Medical Beauty Sector Growth - The medical beauty industry in China is expected to maintain rapid growth due to increasing consumer demand and purchasing power, with a market size of RMB 143.6 billion in 2019, making it the second-largest market globally[32]. - The compound annual growth rate (CAGR) of the medical beauty market from 2015 to 2019 was 22.5%, and from 2016 to 2020, it was 18.9%, indicating robust growth despite the pandemic[32]. - The medical beauty segment has shown steady revenue growth, with the acquisition of two medical beauty hospitals contributing positively to performance[36]. - The company aims to optimize its asset structure and enhance operational efficiency by focusing on the medical beauty sector, moving away from real estate[36]. - The medical beauty market in China has significant growth potential, with low penetration rates compared to international markets, indicating room for expansion[32]. Strategic Partnerships and Acquisitions - The company established a strategic partnership with Shaoxing Chun Natural Fiber Membrane Co., Ltd. to upgrade traditional production lines and invest in high-end medical beauty cellulose membrane production lines[38]. - The company acquired Guangdong Aurora Health Management Consulting Co., Ltd. to enhance its "light medical beauty" business model, covering a wide range of services from basic skincare to advanced aesthetic treatments[41]. - The company acquired a 55% stake in Zhejiang Liantian Beauty Management Co., Ltd. for ¥696,666,700.00, with the equity transfer completed during the reporting period[86]. - The company completed the acquisition of 100% equity of Guangdong Aurora Health Management Consulting Co., Ltd. in October 2021, which is now a controlling subsidiary and is operating steadily[159]. Research and Development - The company is focusing on the integration of medical beauty technology and product development, collaborating with academic institutions for innovation[52]. - The company has established a dedicated R&D team for cellulose film used in adhesive tape, focusing on production process parameters and quality requirements[73]. - The company aims to enhance the performance of cellulose films to expand their applicability in various industries, including food and pharmaceuticals[74]. - The company increased its R&D personnel from 149 in 2020 to 176 in 2021, representing an 18.12% growth[74]. - R&D investment rose to ¥26,310,327.93 in 2021, a 39.03% increase from ¥18,924,275.97 in 2020, with R&D expenditure accounting for 1.71% of operating revenue[74]. Governance and Management - The company held 6 shareholder meetings during the reporting period, ensuring equal voting rights for all shareholders, especially minority shareholders[114]. - The board of directors consists of 9 members, including 3 independent directors, and held 14 meetings during the reporting period[115]. - The company maintains independent operations in business, personnel, assets, and finance, ensuring no interference from controlling shareholders[114]. - The company has established four specialized committees under the board of directors to provide professional opinions for decision-making[115]. - The company is committed to improving its governance structure in compliance with relevant laws and regulations[114]. Environmental Management - The wastewater treatment facilities operated normally in 2021, with a total operating cost of 23.03 million yuan[173]. - The water purification treatment station has a daily processing capacity of 54,500 tons and achieved a COD removal rate of 96.35%[173]. - The company has installed online monitoring systems for wastewater and flue gas emissions to ensure compliance with environmental standards[174]. - The company has taken corrective measures in response to any administrative penalties related to environmental issues[174]. - The company prioritizes environmental protection and energy conservation, adhering to relevant regulations to control pollutant emissions during production[178]. Financial Management and Reporting - The company reported a financing balance of CNY 1,389,046,318, with bank loans accounting for CNY 1,201,500,000 and non-bank loans for CNY 187,546,318[47]. - The average financing cost for bank loans ranges from 5.8% to 6.5%, while non-bank loans range from 6% to 6.3%[47]. - The company reported a total investment of CNY 201,123,713.39 in fixed assets, with a cumulative actual investment of CNY 1,756,530,605.00 by the end of the reporting period[88]. - The company recognized goodwill of ¥661,092,881.52 due to the acquisition of the medical beauty business, reflecting a significant increase from ¥11,568,395.68 in the previous year[78]. - The company reported no violations regarding external guarantees during the reporting period[196].